EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

Detalles Bibliográficos
Autores principales: Piccolo, F, Tosh, J, De Boisvilliers, S, Patel, S, Patel, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747461/
http://dx.doi.org/10.1016/j.jval.2022.09.710
_version_ 1784849604350574592
author Piccolo, F
Tosh, J
De Boisvilliers, S
Patel, S
Patel, V
author_facet Piccolo, F
Tosh, J
De Boisvilliers, S
Patel, S
Patel, V
author_sort Piccolo, F
collection PubMed
description
format Online
Article
Text
id pubmed-9747461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-97474612022-12-14 EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy Piccolo, F Tosh, J De Boisvilliers, S Patel, S Patel, V Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747461/ http://dx.doi.org/10.1016/j.jval.2022.09.710 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Piccolo, F
Tosh, J
De Boisvilliers, S
Patel, S
Patel, V
EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
title EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
title_full EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
title_fullStr EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
title_full_unstemmed EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
title_short EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
title_sort ee465 cost-effectiveness of sotrovimab for the treatment of mild-to-moderate covid-19 in patients at high risk of disease progression in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747461/
http://dx.doi.org/10.1016/j.jval.2022.09.710
work_keys_str_mv AT piccolof ee465costeffectivenessofsotrovimabforthetreatmentofmildtomoderatecovid19inpatientsathighriskofdiseaseprogressioninitaly
AT toshj ee465costeffectivenessofsotrovimabforthetreatmentofmildtomoderatecovid19inpatientsathighriskofdiseaseprogressioninitaly
AT deboisvillierss ee465costeffectivenessofsotrovimabforthetreatmentofmildtomoderatecovid19inpatientsathighriskofdiseaseprogressioninitaly
AT patels ee465costeffectivenessofsotrovimabforthetreatmentofmildtomoderatecovid19inpatientsathighriskofdiseaseprogressioninitaly
AT patelv ee465costeffectivenessofsotrovimabforthetreatmentofmildtomoderatecovid19inpatientsathighriskofdiseaseprogressioninitaly

Ejemplares similares